---
document_datetime: 2025-12-17 23:06:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/scemblix.html
document_name: scemblix.html
version: success
processing_time: 0.0870922
conversion_datetime: 2025-12-24 06:17:49.164436
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Scemblix

[RSS](/en/individual-human-medicine.xml/67592)

##### Authorised

This medicine is authorised for use in the European Union

asciminib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Scemblix](#news-on)
- [More information on Scemblix](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Scemblix is a cancer medicine. It is used to treat chronic myeloid leukaemia (CML), a cancer of the white blood cells, in the 'chronic' phase (this is when the cancer is developing slowly and the patient has few or no symptoms).

It is used in adults whose cancer is 'Philadelphiachromosome positive' (Ph+). Ph+ means that two of the patient's chromosomes have rearranged themselves and formed a special chromosome called the Philadelphia chromosome. This chromosome produces an enzyme (protein) known as BCR::ABL1 kinase, that leads to the development of leukaemia.

CML is rare, and Scemblix was designated an 'orphan medicine' (a medicine used in rare diseases) on 24 March 2020. Further information on the orphan designation can be found here: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2261

Scemblix contains the active substance asciminib.

Expand section

Collapse section

## How is Scemblix used?

Scemblix can only be obtained with a prescription and treatment must be started by a doctor who is experienced in the diagnosis and treatment of leukaemia.

The medicine is available as tablets to be taken by mouth twice a day. The doctor may interrupt treatment and reduce the dose if certain side effects occur. Treatment may be stopped if a patient cannot tolerate treatment with the reduced dose.

For more information about using Scemblix, see the package leaflet or contact your doctor or pharmacist.

## How does Scemblix work?

The active substance in Scemblix, asciminib, is a tyrosine kinase inhibitor (TKI), meaning that it blocks enzymes known as tyrosine kinases. In Ph+ CML, the body produces large numbers of abnormal white blood cells. Scemblix specifically blocks the action of the BCR::ABL1 tyrosine kinase that is produced by these cells, and this stops their division and growth.

## What benefits of Scemblix have been shown in studies?

The benefits of Scemblix were evaluated in a main study in 233 adults with Ph+ CML in the chronic phase who were previously treated with two or more tyrosine kinase inhibitors. In this study, Scemblix was more effective than bosutinib (another tyrosine kinase inhibitor): after 24 weeks of treatment, 25% (40 out of 157) of patients given Scemblix had a major molecular response (meaning that the number of cells with the *BCR::ABL1* gene had decreased to 1,000 times below the standardised baseline), compared with 13% (10 out of 76) of patients given bosutinib. After 96 weeks of treatment, 38% (59 out of 157) of patients given Scemblix and 16% (12 out of 76) of patients given bosutinib had a major molecular response.

## What are the risks associated with Scemblix?

The most common side effects with Scemblix (which may affect more than 2 in 10 people) are pain in the muscles, joints and bones, upper respiratory tract (nose and throat) infections, thrombocytopenia (low levels of blood platelets), tiredness, headache, increased levels of pancreatic enzymes, abdominal pain, diarrhoea and nausea (feeling sick).

The most common serious side effects with Scemblix (which may affect up to 1 in 10 people) are pleural effusion (fluid around the lungs), lower respiratory tract infections (infections of the lungs, such as bronchitis or pneumonia), thrombocytopenia, fever, pancreatitis (inflammation of the pancreas), chest pain (not related to the heart) and vomiting.

For the full list of side effects and restrictions of Scemblix, see the package leaflet.

## Why is Scemblix authorised in the EU?

Scemblix has been shown to be more effective than another tyrosine kinase inhibitor at reducing the number of cells with the *BCR::ABL1* gene in patients who had already received at least two previous tyrosine kinase inhibitors. In terms of safety, the side effects with Scemblix are similar to those seen with this class of medicines and are considered manageable. The European Medicines Agency therefore decided that the benefits of Scemblix are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Scemblix?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Scemblix have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Scemblix are continuously monitored. Suspected side effects reported with Scemblix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Scemblix

Scemblix received a marketing authorisation valid throughout the EU on 25 August 2022.

Scemblix : EPAR - Medicine Overview

Reference Number: EMADOC-1829012207-33715

English (EN) (118.31 KB - PDF)

**First published:** 07/09/2022

**Last updated:** 08/12/2025

[View](/en/documents/overview/scemblix-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-590)

български (BG) (135.26 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/bg/documents/overview/scemblix-epar-medicine-overview_bg.pdf)

español (ES) (107.16 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/es/documents/overview/scemblix-epar-medicine-overview_es.pdf)

čeština (CS) (131.51 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/cs/documents/overview/scemblix-epar-medicine-overview_cs.pdf)

dansk (DA) (108.22 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/da/documents/overview/scemblix-epar-medicine-overview_da.pdf)

Deutsch (DE) (110.22 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/de/documents/overview/scemblix-epar-medicine-overview_de.pdf)

eesti keel (ET) (94.58 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/et/documents/overview/scemblix-epar-medicine-overview_et.pdf)

ελληνικά (EL) (143.35 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/el/documents/overview/scemblix-epar-medicine-overview_el.pdf)

français (FR) (108.91 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/fr/documents/overview/scemblix-epar-medicine-overview_fr.pdf)

hrvatski (HR) (130.46 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/hr/documents/overview/scemblix-epar-medicine-overview_hr.pdf)

italiano (IT) (106.75 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/it/documents/overview/scemblix-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (138.45 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/lv/documents/overview/scemblix-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.79 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/lt/documents/overview/scemblix-epar-medicine-overview_lt.pdf)

magyar (HU) (131.88 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/hu/documents/overview/scemblix-epar-medicine-overview_hu.pdf)

Malti (MT) (133.82 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/mt/documents/overview/scemblix-epar-medicine-overview_mt.pdf)

Nederlands (NL) (107.81 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/nl/documents/overview/scemblix-epar-medicine-overview_nl.pdf)

polski (PL) (136.64 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/pl/documents/overview/scemblix-epar-medicine-overview_pl.pdf)

português (PT) (108.36 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/pt/documents/overview/scemblix-epar-medicine-overview_pt.pdf)

română (RO) (127.85 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/ro/documents/overview/scemblix-epar-medicine-overview_ro.pdf)

slovenčina (SK) (131.42 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/sk/documents/overview/scemblix-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.11 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/sl/documents/overview/scemblix-epar-medicine-overview_sl.pdf)

Suomi (FI) (105.32 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/fi/documents/overview/scemblix-epar-medicine-overview_fi.pdf)

svenska (SV) (105.91 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/sv/documents/overview/scemblix-epar-medicine-overview_sv.pdf)

Scemblix : EPAR - Risk management plan

English (EN) (37.49 MB - PDF)

**First published:** 07/09/2022

**Last updated:** 08/12/2025

[View](/en/documents/rmp/scemblix-epar-risk-management-plan_en.pdf)

## Product information

Scemblix : EPAR - Product Information

English (EN) (460.5 KB - PDF)

**First published:** 07/09/2022

**Last updated:** 08/12/2025

[View](/en/documents/product-information/scemblix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-819)

български (BG) (1.71 MB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/bg/documents/product-information/scemblix-epar-product-information_bg.pdf)

español (ES) (481.11 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/es/documents/product-information/scemblix-epar-product-information_es.pdf)

čeština (CS) (466.39 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/cs/documents/product-information/scemblix-epar-product-information_cs.pdf)

dansk (DA) (470.6 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/da/documents/product-information/scemblix-epar-product-information_da.pdf)

Deutsch (DE) (466.53 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/de/documents/product-information/scemblix-epar-product-information_de.pdf)

eesti keel (ET) (449.22 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/et/documents/product-information/scemblix-epar-product-information_et.pdf)

ελληνικά (EL) (547.51 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/el/documents/product-information/scemblix-epar-product-information_el.pdf)

français (FR) (487.74 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/fr/documents/product-information/scemblix-epar-product-information_fr.pdf)

hrvatski (HR) (486.84 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/hr/documents/product-information/scemblix-epar-product-information_hr.pdf)

íslenska (IS) (445.35 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/is/documents/product-information/scemblix-epar-product-information_is.pdf)

italiano (IT) (438.81 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/it/documents/product-information/scemblix-epar-product-information_it.pdf)

latviešu valoda (LV) (477.37 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/lv/documents/product-information/scemblix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (494.26 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/lt/documents/product-information/scemblix-epar-product-information_lt.pdf)

magyar (HU) (502.5 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/hu/documents/product-information/scemblix-epar-product-information_hu.pdf)

Malti (MT) (492.1 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/mt/documents/product-information/scemblix-epar-product-information_mt.pdf)

Nederlands (NL) (435.63 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/nl/documents/product-information/scemblix-epar-product-information_nl.pdf)

norsk (NO) (409.16 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/no/documents/product-information/scemblix-epar-product-information_no.pdf)

polski (PL) (473.53 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/pl/documents/product-information/scemblix-epar-product-information_pl.pdf)

português (PT) (490.65 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/pt/documents/product-information/scemblix-epar-product-information_pt.pdf)

română (RO) (471.55 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/ro/documents/product-information/scemblix-epar-product-information_ro.pdf)

slovenčina (SK) (488.18 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/sk/documents/product-information/scemblix-epar-product-information_sk.pdf)

slovenščina (SL) (482.16 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/sl/documents/product-information/scemblix-epar-product-information_sl.pdf)

Suomi (FI) (438.45 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/fi/documents/product-information/scemblix-epar-product-information_fi.pdf)

svenska (SV) (436.89 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

08/12/2025

[View](/sv/documents/product-information/scemblix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000265010 17/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Scemblix : EPAR - All authorised presentations

English (EN) (56.07 KB - PDF)

**First published:** 07/09/2022

**Last updated:** 15/12/2022

[View](/en/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-622)

български (BG) (64.84 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/bg/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.84 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/es/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.27 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/cs/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.31 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/da/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (46.81 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/de/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (56.19 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/et/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.31 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/el/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_el.pdf)

français (FR) (64.99 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/fr/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (58.68 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/hr/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (59.14 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/is/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (59.14 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/it/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.91 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/lv/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.1 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/lt/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.89 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/hu/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (49.78 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/mt/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.79 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/nl/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.16 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/no/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.64 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/pl/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_pl.pdf)

português (PT) (56.89 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/pt/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.69 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/ro/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/sk/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (60.04 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/sl/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (56.12 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/fi/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.76 KB - PDF)

**First published:**

07/09/2022

**Last updated:**

15/12/2022

[View](/sv/documents/all-authorised-presentations/scemblix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Scemblix Active substance asciminib hydrochloride International non-proprietary name (INN) or common name asciminib Therapeutic area (MeSH) Leukemia, Myelogenous, Chronic, BCR-ABL Positive Anatomical therapeutic chemical (ATC) code L01EA06

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005605

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 23/06/2022 Marketing authorisation issued 25/08/2022 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Scemblix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.89 KB - PDF)

**First published:** 22/04/2025

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/scemblix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Scemblix : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (149.51 KB - PDF)

**First published:** 15/12/2022

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/scemblix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Scemblix : Orphan maintenance assessment report (post authorisation)

Reference Number: EMADOC-360526170-2697193

English (EN) (388.79 KB - PDF)

**First published:** 08/12/2025

[View](/en/documents/orphan-maintenance-report-post/scemblix-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Scemblix-VR-0000265010 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMADOC-1700519818-2475374

English (EN) (6.43 MB - PDF)

**First published:** 08/12/2025

[View](/en/documents/variation-report/scemblix-vr-0000265010-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Scemblix (II-EMAVR0000265010)

Adopted

Reference Number: EMADOC-1700519818-2475296

English (EN) (123.42 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-scemblix-ii-emavr0000265010_en.pdf)

Scemblix-PAM-0000244440 (H-C-005605-P46) : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-1838283

English (EN) (357.45 KB - PDF)

**First published:** 22/04/2025

[View](/en/documents/variation-report/scemblix-pam-0000244440-h-c-005605-p46-epar-assessment-report_en.pdf)

Scemblix-H-C-PSUSA-00011008-202310 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/236201/2024

English (EN) (124.74 KB - PDF)

**First published:** 08/08/2024

[View](/en/documents/scientific-conclusion/scemblix-h-c-psusa-00011008-202310-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Scemblix-H-C-PSUSA-00011008-202210 EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/348807/2023

English (EN) (127.12 KB - PDF)

**First published:** 22/09/2023

[View](/en/documents/scientific-conclusion/scemblix-h-c-psusa-00011008-202210-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Scemblix : EPAR - Orphan Maintenance Assessment Report

Adopted

Reference Number: EMA/OD/0000068920

English (EN) (2.63 MB - PDF)

**First published:** 07/09/2022

[View](/en/documents/orphan-maintenance-report/scemblix-epar-orphan-maintenance-assessment-report_en.pdf)

Scemblix : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/634238/2022

English (EN) (3.35 MB - PDF)

**First published:** 07/09/2022

[View](/en/documents/assessment-report/scemblix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Scemblix

Adopted

Reference Number: EMA/CHMP/587767/2022

English (EN) (128.5 KB - PDF)

**First published:** 24/06/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-scemblix_en.pdf)

#### News on Scemblix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 October 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-october-2025) 17/10/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022) 24/06/2022

#### More information on Scemblix

- [EU/3/20/2261 - orphan designation for treatment of chronic myeloid leukaemia](/en/medicines/human/orphan-designations/eu-3-20-2261)

**This page was last updated on** 08/12/2025

## Share this page

[Back to top](#main-content)